World Psychiatry最新文献

筛选
英文 中文
Management of generalized anxiety disorder and panic disorder in general health care settings: new WHO recommendations. 普通医疗机构对广泛性焦虑症和惊恐障碍的管理:世界卫生组织的新建议。
IF 73.3 1区 医学
World Psychiatry Pub Date : 2024-02-01 DOI: 10.1002/wps.21172
Brandon Gray, Biksegn Asrat, Elaine Brohan, Neerja Chowdhury, Tarun Dua, Mark van Ommeren
{"title":"Management of generalized anxiety disorder and panic disorder in general health care settings: new WHO recommendations.","authors":"Brandon Gray, Biksegn Asrat, Elaine Brohan, Neerja Chowdhury, Tarun Dua, Mark van Ommeren","doi":"10.1002/wps.21172","DOIUrl":"10.1002/wps.21172","url":null,"abstract":"","PeriodicalId":49357,"journal":{"name":"World Psychiatry","volume":"23 1","pages":"160-161"},"PeriodicalIF":73.3,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10785994/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139425856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cumulative remission rate after sequential treatments in depression: reappraisal of the STAR*D trial data. 抑郁症连续治疗后的累积缓解率:对 STAR*D 试验数据的重新评估。
IF 60.5 1区 医学
World Psychiatry Pub Date : 2024-02-01 DOI: 10.1002/wps.21169
Hitoshi Sakurai, Hisashi Noma, Koichiro Watanabe, Hiroyuki Uchida, Toshi A Furukawa
{"title":"Cumulative remission rate after sequential treatments in depression: reappraisal of the STAR*D trial data.","authors":"Hitoshi Sakurai, Hisashi Noma, Koichiro Watanabe, Hiroyuki Uchida, Toshi A Furukawa","doi":"10.1002/wps.21169","DOIUrl":"10.1002/wps.21169","url":null,"abstract":"","PeriodicalId":49357,"journal":{"name":"World Psychiatry","volume":"23 1","pages":"156-157"},"PeriodicalIF":60.5,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10785965/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139425845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Functional magnetic resonance imaging in schizophrenia: current evidence, methodological advances, limitations and future directions. 精神分裂症的功能磁共振成像:当前证据、方法学进展、局限性和未来方向。
IF 60.5 1区 医学
World Psychiatry Pub Date : 2024-02-01 DOI: 10.1002/wps.21159
Aristotle N Voineskos, Colin Hawco, Nicholas H Neufeld, Jessica A Turner, Stephanie H Ameis, Alan Anticevic, Robert W Buchanan, Kristin Cadenhead, Paola Dazzan, Erin W Dickie, Julia Gallucci, Adrienne C Lahti, Anil K Malhotra, Dost Öngür, Todd Lencz, Deepak K Sarpal, Lindsay D Oliver
{"title":"Functional magnetic resonance imaging in schizophrenia: current evidence, methodological advances, limitations and future directions.","authors":"Aristotle N Voineskos, Colin Hawco, Nicholas H Neufeld, Jessica A Turner, Stephanie H Ameis, Alan Anticevic, Robert W Buchanan, Kristin Cadenhead, Paola Dazzan, Erin W Dickie, Julia Gallucci, Adrienne C Lahti, Anil K Malhotra, Dost Öngür, Todd Lencz, Deepak K Sarpal, Lindsay D Oliver","doi":"10.1002/wps.21159","DOIUrl":"10.1002/wps.21159","url":null,"abstract":"<p><p>Functional neuroimaging emerged with great promise and has provided fundamental insights into the neurobiology of schizophrenia. However, it has faced challenges and criticisms, most notably a lack of clinical translation. This paper provides a comprehensive review and critical summary of the literature on functional neuroimaging, in particular functional magnetic resonance imaging (fMRI), in schizophrenia. We begin by reviewing research on fMRI biomarkers in schizophrenia and the clinical high risk phase through a historical lens, moving from case-control regional brain activation to global connectivity and advanced analytical approaches, and more recent machine learning algorithms to identify predictive neuroimaging features. Findings from fMRI studies of negative symptoms as well as of neurocognitive and social cognitive deficits are then reviewed. Functional neural markers of these symptoms and deficits may represent promising treatment targets in schizophrenia. Next, we summarize fMRI research related to antipsychotic medication, psychotherapy and psychosocial interventions, and neurostimulation, including treatment response and resistance, therapeutic mechanisms, and treatment targeting. We also review the utility of fMRI and data-driven approaches to dissect the heterogeneity of schizophrenia, moving beyond case-control comparisons, as well as methodological considerations and advances, including consortia and precision fMRI. Lastly, limitations and future directions of research in the field are discussed. Our comprehensive review suggests that, in order for fMRI to be clinically useful in the care of patients with schizophrenia, research should address potentially actionable clinical decisions that are routine in schizophrenia treatment, such as which antipsychotic should be prescribed or whether a given patient is likely to have persistent functional impairment. The potential clinical utility of fMRI is influenced by and must be weighed against cost and accessibility factors. Future evaluations of the utility of fMRI in prognostic and treatment response studies may consider including a health economics analysis.</p>","PeriodicalId":49357,"journal":{"name":"World Psychiatry","volume":"23 1","pages":"26-51"},"PeriodicalIF":60.5,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10786022/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139425851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genetics for mental health clinicians: a call for a globally accessible and equitable psychiatric genetics education. 精神卫生临床医生的遗传学:呼吁在全球范围内开展公平的精神遗传学教育。
IF 60.5 1区 医学
World Psychiatry Pub Date : 2024-02-01 DOI: 10.1002/wps.21173
{"title":"Genetics for mental health clinicians: a call for a globally accessible and equitable psychiatric genetics education.","authors":"","doi":"10.1002/wps.21173","DOIUrl":"10.1002/wps.21173","url":null,"abstract":"","PeriodicalId":49357,"journal":{"name":"World Psychiatry","volume":"23 1","pages":"161-163"},"PeriodicalIF":60.5,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10785985/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139425854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk of new-onset psychiatric sequelae of COVID-19 in the early and late post-acute phase. COVID - 19急性期早期和晚期新发精神后遗症的风险
IF 73.3 1区 医学
World Psychiatry Pub Date : 2022-06-01 DOI: 10.1002/wps.20992
Ben Coleman, Elena Casiraghi, Hannah Blau, Lauren Chan, Melissa A Haendel, Bryan Laraway, Tiffany J Callahan, Rachel R Deer, Kenneth J Wilkins, Justin Reese, Peter N Robinson
{"title":"Risk of new-onset psychiatric sequelae of COVID-19 in the early and late post-acute phase.","authors":"Ben Coleman,&nbsp;Elena Casiraghi,&nbsp;Hannah Blau,&nbsp;Lauren Chan,&nbsp;Melissa A Haendel,&nbsp;Bryan Laraway,&nbsp;Tiffany J Callahan,&nbsp;Rachel R Deer,&nbsp;Kenneth J Wilkins,&nbsp;Justin Reese,&nbsp;Peter N Robinson","doi":"10.1002/wps.20992","DOIUrl":"10.1002/wps.20992","url":null,"abstract":"319 half of the originally randomized sample. However, almost half (43.8%) of the omitted participants simply did not receive the assessment needed to diagnose PGD, and another 38% were excluded because it was too soon (six months to one year since the loss) to receive a PGD diagnosis. Further, those assessed showed no differences in demographic or clinical characteristics from participants in the parent study. We endorse continued study of effective treatments for PGD. In the meantime, we believe that clinicians will benefit from knowing that CGT, a strongly validated intervention, can be appropriately re-labeled as prolonged grief disorder therapy (PGDT).","PeriodicalId":49357,"journal":{"name":"World Psychiatry","volume":"21 1","pages":"319-320"},"PeriodicalIF":73.3,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077621/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46561566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
Prevention, treatment and care of substance use disorders in times of COVID-19. COVID - 19期间物质使用障碍的预防、治疗和护理
IF 60.5 1区 医学
World Psychiatry Pub Date : 2022-06-01 DOI: 10.1002/wps.20995
Nora D Volkow, Susan Maua, Giovanna Campello, Vladimir Poznyak, Dzmitry Krupchanka, Wataru Kashino, Anja Busse
{"title":"Prevention, treatment and care of substance use disorders in times of COVID-19.","authors":"Nora D Volkow, Susan Maua, Giovanna Campello, Vladimir Poznyak, Dzmitry Krupchanka, Wataru Kashino, Anja Busse","doi":"10.1002/wps.20995","DOIUrl":"10.1002/wps.20995","url":null,"abstract":"","PeriodicalId":49357,"journal":{"name":"World Psychiatry","volume":"21 1","pages":"323-324"},"PeriodicalIF":60.5,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077610/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45037505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patterns and correlates of patient-reported helpfulness of treatment for common mental and substance use disorders in the WHO World Mental Health Surveys. 世卫组织世界精神卫生调查中患者报告的对治疗常见精神和物质使用障碍的帮助程度的模式和相关因素
IF 60.5 1区 医学
World Psychiatry Pub Date : 2022-06-01 DOI: 10.1002/wps.20971
Ronald C Kessler, Alan E Kazdin, Sergio Aguilar-Gaxiola, Ali Al-Hamzawi, Jordi Alonso, Yasmin A Altwaijri, Laura H Andrade, Corina Benjet, Chrianna Bharat, Guilherme Borges, Ronny Bruffaerts, Brendan Bunting, José Miguel Caldas de Almeida, Graça Cardoso, Wai Tat Chiu, Alfredo Cía, Marius Ciutan, Louisa Degenhardt, Giovanni de Girolamo, Peter de Jonge, Ymkje Anna de Vries, Silvia Florescu, Oye Gureje, Josep Maria Haro, Meredith G Harris, Chiyi Hu, Aimee N Karam, Elie G Karam, Georges Karam, Norito Kawakami, Andrzej Kiejna, Viviane Kovess-Masfety, Sing Lee, Victor Makanjuola, John J McGrath, Maria Elena Medina-Mora, Jacek Moskalewicz, Fernando Navarro-Mateu, Andrew A Nierenberg, Daisuke Nishi, Akin Ojagbemi, Bibilola D Oladeji, Siobhan O'Neill, José Posada-Villa, Victor Puac-Polanco, Charlene Rapsey, Ayelet Meron Ruscio, Nancy A Sampson, Kate M Scott, Tim Slade, Juan Carlos Stagnaro, Dan J Stein, Hisateru Tachimori, Margreet Ten Have, Yolanda Torres, Maria Carmen Viana, Daniel V Vigo, David R Williams, Bogdan Wojtyniak, Miguel Xavier, Zahari Zarkov, Hannah N Ziobrowski
{"title":"Patterns and correlates of patient-reported helpfulness of treatment for common mental and substance use disorders in the WHO World Mental Health Surveys.","authors":"Ronald C Kessler, Alan E Kazdin, Sergio Aguilar-Gaxiola, Ali Al-Hamzawi, Jordi Alonso, Yasmin A Altwaijri, Laura H Andrade, Corina Benjet, Chrianna Bharat, Guilherme Borges, Ronny Bruffaerts, Brendan Bunting, José Miguel Caldas de Almeida, Graça Cardoso, Wai Tat Chiu, Alfredo Cía, Marius Ciutan, Louisa Degenhardt, Giovanni de Girolamo, Peter de Jonge, Ymkje Anna de Vries, Silvia Florescu, Oye Gureje, Josep Maria Haro, Meredith G Harris, Chiyi Hu, Aimee N Karam, Elie G Karam, Georges Karam, Norito Kawakami, Andrzej Kiejna, Viviane Kovess-Masfety, Sing Lee, Victor Makanjuola, John J McGrath, Maria Elena Medina-Mora, Jacek Moskalewicz, Fernando Navarro-Mateu, Andrew A Nierenberg, Daisuke Nishi, Akin Ojagbemi, Bibilola D Oladeji, Siobhan O'Neill, José Posada-Villa, Victor Puac-Polanco, Charlene Rapsey, Ayelet Meron Ruscio, Nancy A Sampson, Kate M Scott, Tim Slade, Juan Carlos Stagnaro, Dan J Stein, Hisateru Tachimori, Margreet Ten Have, Yolanda Torres, Maria Carmen Viana, Daniel V Vigo, David R Williams, Bogdan Wojtyniak, Miguel Xavier, Zahari Zarkov, Hannah N Ziobrowski","doi":"10.1002/wps.20971","DOIUrl":"10.1002/wps.20971","url":null,"abstract":"<p><p>Patient-reported helpfulness of treatment is an important indicator of quality in patient-centered care. We examined its pathways and predictors among respondents to household surveys who reported ever receiving treatment for major depression, generalized anxiety disorder, social phobia, specific phobia, post-traumatic stress disorder, bipolar disorder, or alcohol use disorder. Data came from 30 community epidemiological surveys - 17 in high-income countries (HICs) and 13 in low- and middle-income countries (LMICs) - carried out as part of the World Health Organization (WHO)'s World Mental Health (WMH) Surveys. Respondents were asked whether treatment of each disorder was ever helpful and, if so, the number of professionals seen before receiving helpful treatment. Across all surveys and diagnostic categories, 26.1% of patients (N=10,035) reported being helped by the very first professional they saw. Persisting to a second professional after a first unhelpful treatment brought the cumulative probability of receiving helpful treatment to 51.2%. If patients persisted with up through eight professionals, the cumulative probability rose to 90.6%. However, only an estimated 22.8% of patients would have persisted in seeing these many professionals after repeatedly receiving treatments they considered not helpful. Although the proportion of individuals with disorders who sought treatment was higher and they were more persistent in HICs than LMICs, proportional helpfulness among treated cases was no different between HICs and LMICs. A wide range of predictors of perceived treatment helpfulness were found, some of them consistent across diagnostic categories and others unique to specific disorders. These results provide novel information about patient evaluations of treatment across diagnoses and countries varying in income level, and suggest that a critical issue in improving the quality of care for mental disorders should be fostering persistence in professional help-seeking if earlier treatments are not helpful.</p>","PeriodicalId":49357,"journal":{"name":"World Psychiatry","volume":" ","pages":"272-286"},"PeriodicalIF":60.5,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077614/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45958830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reasons why people may refuse COVID‐19 vaccination (and what can be done about it) 人们可能拒绝接种新冠疫苗的原因(以及可以采取的措施)
IF 73.3 1区 医学
World Psychiatry Pub Date : 2022-05-07 DOI: 10.1002/wps.20990
M. Hornsey
{"title":"Reasons why people may refuse COVID‐19 vaccination (and what can be done about it)","authors":"M. Hornsey","doi":"10.1002/wps.20990","DOIUrl":"https://doi.org/10.1002/wps.20990","url":null,"abstract":"","PeriodicalId":49357,"journal":{"name":"World Psychiatry","volume":"21 1","pages":"217 - 218"},"PeriodicalIF":73.3,"publicationDate":"2022-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44037982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Oral and long‐acting antipsychotics for relapse prevention in schizophrenia‐spectrum disorders: a network meta‐analysis of 92 randomized trials including 22,645 participants 口服和长效抗精神病药物预防精神分裂症谱系障碍复发:92项随机试验的网络荟萃分析,包括22645名参与者
IF 73.3 1区 医学
World Psychiatry Pub Date : 2022-05-07 DOI: 10.1002/wps.20972
G. Ostuzzi, F. Bertolini, F. Tedeschi, Giovanni Vita, P. Brambilla, L. Fabro, C. Gastaldon, D. Papola, M. Purgato, Guido Nosari, C. Del Giovane, C. Correll, C. Barbui
{"title":"Oral and long‐acting antipsychotics for relapse prevention in schizophrenia‐spectrum disorders: a network meta‐analysis of 92 randomized trials including 22,645 participants","authors":"G. Ostuzzi, F. Bertolini, F. Tedeschi, Giovanni Vita, P. Brambilla, L. Fabro, C. Gastaldon, D. Papola, M. Purgato, Guido Nosari, C. Del Giovane, C. Correll, C. Barbui","doi":"10.1002/wps.20972","DOIUrl":"https://doi.org/10.1002/wps.20972","url":null,"abstract":"According to current evidence and guidelines, continued antipsychotic treatment is key for preventing relapse in people with schizophrenia‐spectrum disorders, but evidence‐based recommendations for the choice of the individual antipsychotic for maintenance treatment are lacking. Although oral antipsychotics are often prescribed first line for practical reasons, long‐acting injectable antipsychotics (LAIs) are a valuable resource to tackle adherence issues since the earliest phase of disease. Medline, EMBASE, PsycINFO, CENTRAL and CINAHL databases and online registers were searched to identify randomized controlled trials comparing LAIs or oral antipsychotics head‐to‐head or against placebo, published until June 2021. Relative risks and standardized mean differences were pooled using random‐effects pairwise and network meta‐analysis. The primary outcomes were relapse and dropout due to adverse events. We used the Cochrane Risk of Bias tool to assess study quality, and the CINeMA approach to assess the confidence of pooled estimates. Of 100 eligible trials, 92 (N=22,645) provided usable data for meta‐analyses. Regarding relapse prevention, the vast majority of the 31 included treatments outperformed placebo. Compared to placebo, “high” confidence in the results was found for (in descending order of effect magnitude) amisulpride‐oral (OS), olanzapine‐OS, aripiprazole‐LAI, olanzapine‐LAI, aripiprazole‐OS, paliperidone‐OS, and ziprasidone‐OS. “Moderate” confidence in the results was found for paliperidone‐LAI 1‐monthly, iloperidone‐OS, fluphenazine‐OS, brexpiprazole‐OS, paliperidone‐LAI 1‐monthly, asenapine‐OS, haloperidol‐OS, quetiapine‐OS, cariprazine‐OS, and lurasidone‐OS. Regarding tolerability, none of the antipsychotics was significantly worse than placebo, but confidence was poor, with only aripiprazole (both LAI and OS) showing “moderate” confidence levels. Based on these findings, olanzapine, aripiprazole and paliperidone are the best choices for the maintenance treatment of schizophrenia‐spectrum disorders, considering that both LAI and oral formulations of these antipsychotics are among the best‐performing treatments and have the highest confidence of evidence for relapse prevention. This finding is of particular relevance for low‐ and middle‐income countries and constrained‐resource settings, where few medications may be selected. Results from this network meta‐analysis can inform clinical guidelines and national and international drug regulation policies.","PeriodicalId":49357,"journal":{"name":"World Psychiatry","volume":" ","pages":""},"PeriodicalIF":73.3,"publicationDate":"2022-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47199809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 33
The “Meet the WPA Council” Panel at the 21st World Congress of Psychiatry 第21届世界精神病学大会“会见WPA理事会”小组
IF 73.3 1区 医学
World Psychiatry Pub Date : 2022-05-07 DOI: 10.1002/wps.20957
A. Okasha
{"title":"The “Meet the WPA Council” Panel at the 21st World Congress of Psychiatry","authors":"A. Okasha","doi":"10.1002/wps.20957","DOIUrl":"https://doi.org/10.1002/wps.20957","url":null,"abstract":"","PeriodicalId":49357,"journal":{"name":"World Psychiatry","volume":" ","pages":""},"PeriodicalIF":73.3,"publicationDate":"2022-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44067894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信